The abstract is read at the publisher; the summary is JClub's.
Weekly 1 mg/kg subcutaneous 1687 treatment in severe Trex1−/− AGS1 mice significantly improves survival over 250 days and partially normalizes growth and disease signs.
- Why it matters: AGS1 is driven by cytoplasmic DNA sensing, but its lupus-like clinical overlap suggests extracellular nucleic acids may amplify autoimmunity beyond intracellular triggers.
- What they did: Trex1−/− mice received 1687 (1687, a dual-acting DNase1/DNase1L3 biologic) weekly for 250 days; outcomes included survival, growth, cell-free DNA, autoantibodies, and inflammatory mediators.
- The result: 1687 lowered cell-free DNA, normalized anti-dsDNA and anti-myosin heavy chain 6 autoantibodies, and reduced IFN-γ, CXCL1, and CXCL2, while IFN-α, CCL5, and CXCL9 were unchanged.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.